Rezolute receives innovation passport designation from the u.k. innovative licensing and access pathway steering group for rz358 in the treatment of hypoglycemia due to congenital hyperinsulinism

Redwood city, calif., jan. 23, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the u.k. medicines and healthcare products regulatory agency (mhra) has awarded the innovative medicine designation, the innovation passport, to rz358 for the treatment of hypoglycemia due to congenital hyperinsulinism (hi). the innovation passport designation was granted based on the substantial unmet medical need in this condition and the potential for rz358 to benefit patients as evidenced by the phase 2 rize study in congenital hi, which safely demonstrated significant improvements in hypoglycemia events.
RZLT Ratings Summary
RZLT Quant Ranking